My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 135

    1.

    Pioglitazone treatment improves nitrosative stress in type 2 diabetes.

    Vinik AI, Ullal J, Parson HK, Barlow PM, Casellini CM.

    Diabetes Care. 2006 Apr;29(4):869-76.PMID: 16567830 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus.

    Vinik AI, Stansberry KB, Barlow PM.

    J Diabetes Complications. 2003 Sep-Oct;17(5):279-85.PMID: 12954157 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    4.

    Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

    Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

    J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.PMID: 16306801 [PubMed - indexed for MEDLINE]Related articles

    5.

    The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

    Tooke JE, Elston LM, Gooding KM, Ball CI, Mawson DM, Piper J, Sriraman R, Urquhart R, Shore AC.

    Diabetologia. 2006 May;49(5):1064-70. Epub 2006 Mar 1.PMID: 16508777 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

    Sourij H, Zweiker R, Wascher TC.

    Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    8.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

    Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

    McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF.

    Diabetes Care. 2005 May;28(5):1145-50.PMID: 15855580 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

    Metabolism. 2008 Nov;57(11):1552-7.PMID: 18940393 [PubMed - indexed for MEDLINE]Related articles

    13.

    The role of PPARs in the microvascular dysfunction in diabetes.

    Vinik A, Parson H, Ullal J.

    Vascul Pharmacol. 2006 Jul;45(1):54-64. Epub 2006 Jun 19. Review.PMID: 16784897 [PubMed - indexed for MEDLINE]Related articles

    14.

    Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.

    Rudofsky G Jr, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, Buchbinder S, Zorn M, Humpert PM, Hamann A, Morcos M, Nawroth PP, Bierhaus A.

    Horm Metab Res. 2007 Sep;39(9):665-71.PMID: 17846974 [PubMed - indexed for MEDLINE]Related articles

    15.

    The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

    Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

    Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

    Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

    JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.PMID: 17101640 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

    Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.

    Diabetes Care. 2008 Jan;31(1):121-7. Epub 2007 Oct 1.PMID: 17909084 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.

    Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T.

    Diabetes Technol Ther. 2008 Jun;10(3):206-12.PMID: 18473695 [PubMed - indexed for MEDLINE]Related articles

    19.

    Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

    Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D; GLAL Study Group.

    Diabetes Care. 2005 Mar;28(3):544-50.PMID: 15735185 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity